Millennium Management LLC Raises Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL)

Millennium Management LLC increased its stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) by 96.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,110,298 shares of the company’s stock after purchasing an additional 544,881 shares during the quarter. Millennium Management LLC owned approximately 2.56% of Werewolf Therapeutics worth $2,709,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the company. Janus Henderson Group PLC bought a new position in shares of Werewolf Therapeutics in the first quarter worth approximately $10,922,000. Vanguard Group Inc. increased its holdings in shares of Werewolf Therapeutics by 26.8% in the 1st quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock worth $7,176,000 after buying an additional 233,909 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Werewolf Therapeutics by 22.8% during the 2nd quarter. Acadian Asset Management LLC now owns 212,296 shares of the company’s stock valued at $516,000 after buying an additional 39,413 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Werewolf Therapeutics by 103.1% during the 2nd quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock valued at $417,000 after buying an additional 86,800 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Werewolf Therapeutics by 43.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 160,577 shares of the company’s stock worth $392,000 after acquiring an additional 48,952 shares during the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Werewolf Therapeutics in a report on Tuesday, July 2nd. JMP Securities restated a “market outperform” rating and issued a $12.00 target price on shares of Werewolf Therapeutics in a research report on Wednesday, June 26th.

Werewolf Therapeutics Price Performance

Shares of HOWL opened at $2.01 on Wednesday. The company has a market capitalization of $87.34 million, a P/E ratio of -1.84 and a beta of 0.45. Werewolf Therapeutics, Inc. has a twelve month low of $1.57 and a twelve month high of $8.19. The company has a quick ratio of 12.13, a current ratio of 12.13 and a debt-to-equity ratio of 0.24. The firm has a 50 day moving average of $2.09 and a 200 day moving average of $3.39.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Thursday, August 8th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 48.25%. The business had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $2.00 million. As a group, equities research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.64 earnings per share for the current fiscal year.

Werewolf Therapeutics Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.